Analysis of composite endpoints with component‐wise censoring in the presence of differential visit schedules-Reference-Cited by-同舟云学术

Analysis of composite endpoints with component‐wise censoring in the presence of differential visit schedules

Published:2022-01-18 Issue:9 Volume:41 Page:1599-1612
ISSN:0277-6715
Container-title:Statistics in Medicine
language:en
Short-container-title:Statistics in Medicine

Author:

Eaton Anne A.¹^ORCID,Zabor Emily C.²^ORCID

Affiliation:

1. Division of Biostatistics University of Minnesota Minneapolis Minnesota USA

2. Department of Quantitative Health Sciences & Taussig Cancer Institute Cleveland Clinic Cleveland Ohio USA

Funder

National Cancer Institute

Publisher

Wiley

Subject

Statistics and Probability,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/sim.9312

Reference17 articles.

1. When You Look Matters: The Effect of Assessment Schedule on Progression-Free Survival

2. How to Deal with Interval-Censored Data Practically while Assessing the Progression-Free Survival: A Step-by-Step Guide Using SAS and R Software

3. Sieve estimation in a Markov illness-death process under dual censoring

4. FDA.Clinical trial endpoints for the approval of cancer drugs and biologics guidance for industry; 2018:12;https://www.fda.gov/regulatory‐information/search‐fda‐guidance‐documents/clinical‐trial‐endpoints‐approval‐cancer‐drugs‐and‐biologics.

5. Bias in progression‐free survival analysis due to intermittent assessment of progression

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Statistical approaches for component-wise censored composite endpoints;Clinical Trials;2024-08-08

2. Immunosuppression versus Supportive Care on Kidney Outcomes in IgA Nephropathy in the Real-World Setting;Clinical Journal of the American Society of Nephrology;2023-06-14

3. Performance of Cox regression models for composite time-to-event endpoints with component-wise censoring in randomized trials;Clinical Trials;2023-05-26